Chronic treatment with talipexole dihydrochloride on abnormal involuntary movement in humans.
Two cases of severe dystonia and dyskinesia were treated with talipexole, a dopamine autoreceptor agonist, and the metabolites of dopamine, norepinephrine, and serotonin in cerebrospinal fluid (CSF) were determined. Despite significant reductions in these metabolites in CSF, behavioral amelioration of these cases could not be observed. The present findings argue for further studies to explore the clinical usefulness of dopaminergic agonists such as talipexole.
Nishikawa
T
T
Department of Pharmacology, Kurume University School of Medicine, Japan.
Yamada
S
S
Tsuda
A
A
Tanaka
M
M
Koga
I
I
Uchida
Y
Y
D015102:3,4-Dihydroxyphenylacetic Acid / Q000134:cerebrospinal fluid; D000368:Aged; D001381:Azepines / Q000378:metabolism / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D004421:Dystonia / Q000134:cerebrospinal fluid / Q000188:drug therapy; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000134:cerebrospinal fluid / Q000188:drug therapy*
D001381:Azepines; D015259:Dopamine Agents; D015102:3,4-Dihydroxyphenylacetic Acid; D006897:Hydroxyindoleacetic Acid; C024763:talipexole; D006719:Homovanillic Acid